Search Results - "Lieberman, David B"

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA by Thompson, Jeffrey C, Yee, Stephanie S, Troxel, Andrea B, Savitch, Samantha L, Fan, Ryan, Balli, David, Lieberman, David B, Morrissette, Jennifer D, Evans, Tracey L, Bauml, Joshua, Aggarwal, Charu, Kosteva, John A, Alley, Evan, Ciunci, Christine, Cohen, Roger B, Bagley, Stephen, Stonehouse-Lee, Susan, Sherry, Victoria E, Gilbert, Elizabeth, Langer, Corey, Vachani, Anil, Carpenter, Erica L

“…The expanding number of targeted therapeutics for non-small cell lung cancer (NSCLC) necessitates real-time tumor genotyping, yet tissue biopsies are difficult…”
Get full text

Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma by Gangadhar, Tara C., Savitch, Samantha L., Yee, Stephanie S., Xu, Wei, Huang, Alexander C., Harmon, Shannon, Lieberman, David B., Soucier, Devon, Fan, Ryan, Black, Taylor A., Morrissette, Jennifer J. D., Salathia, Neeraj, Waters, Jill, Zhang, Shile, Toung, Jonathan, Hummelen, Paul, Fan, Jian‐Bing, Xu, Xiaowei, Amaravadi, Ravi K., Schuchter, Lynn M., Karakousis, Giorgos C., Hwang, Wei‐Ting, Carpenter, Erica L.

“…Summary To determine the feasibility of liquid biopsy for monitoring of patients with advanced melanoma, cell‐free DNA was extracted from plasma for 25 Stage…”
Get full text

NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features by Luskin, Marlise R, Huen, Auris O, Brooks, Sarah A, Stewart, Campbell, Watt, Christopher D, Morrissette, Jennifer J D, Lieberman, David B, Bagg, Adam, Rosenbach, Misha, Perl, Alexander E

Get full text

Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing by Hiemenz, Matthew C, Kadauke, Stephan, Lieberman, David B, Roth, David B, Zhao, Jianhua, Watt, Christopher D, Daber, Robert D, Morrissette, Jennifer J D

“…Next-generation sequencing (NGS) is a powerful platform for identifying cancer mutations. Routine clinical adoption of NGS requires optimized quality control…”
Get full text

Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma by Nasrallah, MacLean P., Binder, Zev A., Oldridge, Derek A., Zhao, Jianhua, Lieberman, David B., Roth, Jacquelyn J., Watt, Christopher D., Sukhadia, Shrey, Klinman, Eva, Daber, Robert D., Desai, Arati, Brem, Steven, O’Rourke, Donald M., Morrissette, Jennifer J. D.

“…Molecular profiling of glioblastoma has revealed complex cytogenetic, epigenetic, and molecular abnormalities that are necessary for diagnosis, prognosis, and…”
Get full text

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer by Aggarwal, Charu, Thompson, Jeffrey C, Black, Taylor A, Katz, Sharyn I, Fan, Ryan, Yee, Stephanie S, Chien, Austin L, Evans, Tracey L, Bauml, Joshua M, Alley, Evan W, Ciunci, Christine A, Berman, Abigail T, Cohen, Roger B, Lieberman, David B, Majmundar, Krishna S, Savitch, Samantha L, Morrissette, Jennifer J D, Hwang, Wei-Ting, Elenitoba-Johnson, Kojo S J, Langer, Corey J, Carpenter, Erica L

“…The clinical implications of adding plasma-based circulating tumor DNA next-generation sequencing (NGS) to tissue NGS for targetable mutation detection in…”
Get more information

Germline POT1 variants can predispose to myeloid and lymphoid neoplasms by Lim, Tristan L., Lieberman, David B., Davis, Adam R., Loren, Alison W., Hausler, Ryan, Bigdeli, Ashkan, Li, Yimei, Powers, Jacquelyn, Raper, Anna, Regeneron Genetics Center, Carty, Shannon A., Nathanson, Katherine L., Bagg, Adam, Hexner, Elizabeth O., Maxwell, Kara N., Morrissette, Jennifer J. D., Babushok, Daria V.

Get full text

Germline duplication of ATG2B and GSKIP genes is not required for the familial myeloid malignancy syndrome associated with the duplication of chromosome 14q32 by Babushok, Daria V., Stanley, Natasha L., Morrissette, Jennifer J. D., Lieberman, David B., Olson, Timothy S., Chou, Stella T., Hexner, Elizabeth O.

Get full text

Utilization of next generation sequencing identifies potentially actionable mutations in chronic lymphocytic leukaemia by Wang, Jie, Morrissette, Jennifer, Lieberman, David B., Timlin, Colleen, Schuster, Stephen J., Mato, Anthony R.

Get full text

Validation of a next-generation sequencing oncology panel optimized for low input DNA by Sussman, Robyn T., Shaffer, Sydney, Azzato, Elizabeth M., DeSloover, Daniel, Farooqi, Midhat S., Meyer, Anders, Lieberman, David B., Bigdeli, Ashkan, Paolillo, Carmela, Ganapathy, Karthik, Sukhadia, Shrey, Rosenbaum, Jason N., Daber, Robert D., Morrissette, Jennifer J.D.

“…•Hotspot panel for poor quality and low input oncology specimens.•Assay input DNA as low as 0.5-1 ng. One caveat of next-generation sequencing (NGS)-based…”
Get full text

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors by Fox, Alan J, Hiemenz, Matthew C, Lieberman, David B, Sukhadia, Shrey, Li, Barnett, Grubb, Joseph, Candrea, Patrick, Ganapathy, Karthik, Zhao, Jianhua, Roth, David, Alley, Evan, Loren, Alison, Morrissette, Jennifer J D

“…As our understanding of the driver mutations necessary for initiation and progression of cancers improves, we gain critical information on how specific…”
Get full text

A novel approach for next‐generation sequencing of circulating tumor cells by Yee, Stephanie S., Lieberman, David B., Blanchard, Tatiana, Rader, JulieAnn, Zhao, Jianhua, Troxel, Andrea B., DeSloover, Daniel, Fox, Alan J., Daber, Robert D., Kakrecha, Bijal, Sukhadia, Shrey, Belka, George K., DeMichele, Angela M., Chodosh, Lewis A., Morrissette, Jennifer J. D., Carpenter, Erica L.

“…Background Next‐generation sequencing (NGS) of surgically resected solid tumor samples has become integral to personalized medicine approaches for cancer…”
Get full text

T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy by Ghilardi, Guido, Fraietta, Joseph A., Gerson, James N., Van Deerlin, Vivianna M., Morrissette, Jennifer J. D., Caponetti, Gabriel C., Paruzzo, Luca, Harris, Jaryse C., Chong, Elise A., Susanibar Adaniya, Sandra P., Svoboda, Jakub, Nasta, Sunita D., Ugwuanyi, Ositadimma H., Landsburg, Daniel J., Fardella, Eugenio, Waxman, Adam J., Chong, Emeline R., Patel, Vrutti, Pajarillo, Raymone, Kulikovskaya, Irina, Lieberman, David B., Cohen, Adam D., Levine, Bruce L., Stadtmauer, Edward A., Frey, Noelle V., Vogl, Dan T., Hexner, Elizabeth O., Barta, Stefan K., Porter, David L., Garfall, Alfred L., Schuster, Stephen J., June, Carl H., Ruella, Marco

“…We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The…”
Get full text

DNA Damage Response Constrains Cell Growth and Drives Clonal Hematopoiesis in Telomere Biology Disorders by Sande, Christopher M, Chen, Stone, Mitchell, Dana V, Lin, Ping, Deolikar, Rujul Jagdish, Freeman, Colby, Zhou, Mary, Kumar, Sushant, Zheng, Shannon, Munkhbileg, Bolormaa, Stanley, Natasha L, Guo, Kathy, Hausler, Ryan, Taylor, Deanne M, Corines, James, Morrissette, Jennifer JD, Lieberman, David B, Yang, Guang, Smith-Simmer, Kelcy, Banaszak, Lauren G, Shoger, Kyle, Nicholas, Peter, Walne, Amanda J, Dokal, Inderjeet, Rosenheck, Justin, Churpek, Jane E, Johnson, F Bradley, Olson, Timothy S, Babushok, Daria V

“…Telomere biology disorders (TBD) are inherited diseases caused by genetic defects in telomere maintenance. Patients with TBD have critically shortened…”
Get full text

Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms by Lim, Tristan L., Lieberman, David B., Davis, Adam R., Hausler, Ryan, Bigdeli, Ashkan, Li, Yimei, Powers, Jacquelyn, Genetics Center, Regeneron, Carty, Shannon A., Nathanson, Katherine L., Bagg, Adam, Hexner, Elizabeth O., Maxwell, Kara N., Morrissette, Jennifer J.D., Babushok, Daria V.

“…Germline mutations in the shelterin component protection of telomeres 1 (POT1) were recently found to be associated with familial chronic lymphocytic leukemia…”
Get full text

Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia by McMahon, Christine M., Canaani, Jonathan, Rea, Bryan, Sargent, Rachel Lynn, Morrissette, Jennifer J.D., Lieberman, David B., Watt, Christopher, Schwartz, Gregory W., Faryabi, Robert B., Ferng, Timothy T., Shah, Neil P., Smith, Catherine C., Carroll, Martin, Perl, Alexander E.

“…Introduction: A major mechanism of clinical response to FLT3 tyrosine kinase inhibitors (TKIs) is the induction of terminal granulocytic differentiation of…”
Get full text

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors by Fox, Alan J., Hiemenz, Matthew C., Lieberman, David B., Sukhadia, Shrey, Li, Barnett, Grubb, Joseph, Candrea, Patrick, Ganapathy, Karthik, Zhao, Jianhua, Roth, David, Alley, Evan, Loren, Alison, Morrissette, Jennifer J. D.

Get full text